文献类型：期刊文献

中文题名：生物医药用单原子催化剂的限域载体及其调控机制

英文题名：Confined carrier and regulatory mechanism of single-atom catalysts for biomedical applications

作者：徐世宇[1];尹思源[1];牛德超[1]

机构：[1]华东理工大学材料科学与工程学院,上海200237

年份：2025

卷号：70

期号：23

起止页码：3843

中文期刊名：科学通报

外文期刊名：Chinese Science Bulletin

收录：;EI(收录号：20253218961769);WOS:【ESCI(收录号:WOS:001546457900012)】；北大核心:【北大核心2023】；

基金：国家自然科学基金(32371406);上海市“科技创新行动计划”优秀学术/技术带头人项目(22ZR1415700)资助。

语种：中文

中文关键词：单原子;限域载体;配位结构;调控机制;生物医药

外文关键词：single atom;confined carriers;coordination structure;regulatory mechanism;biomedicine

摘要：自2011年由我国科学家提出“单原子催化”概念以来,单原子催化剂在能源、环境以及生物医药领域显示出巨大的应用潜力.相比于纳米粒子或纳米团簇,单原子催化剂具有最大化的原子利用率、独特的电子结构以及增强的催化活性/选择性等优势.尤其在生物医药领域,金属基单原子催化剂具有一个显著优势,即在复杂的生理环境下不会产生由大量金属离子聚集引发的生物毒性.本文将评述近年来国内外研究者在生物医药用单原子催化剂的限域载体类型、性能调控机制及其在生物医药领域应用方面的最新研究进展.首先,着重介绍单原子催化剂的限域载体类型和催化性能调控机制.然后,通过具体实例阐明单原子催化剂在各种重大疾病诊疗以及生物传感等方面的研究进展.最后,展望生物医药用单原子催化剂的发展和面临的挑战.本文旨在加深人们对单原子催化剂的调控机制以及生物学效应的理解,并推动单原子纳米医学的发展.
Since the concept of“single-atom catalysis”was proposed by Chinese scientists in 2011,single-atom catalysts have attracted great potential for applications in fields such as energy,environment,and biomedicine.Compared to traditional nanoparticle or nanocluster catalysts,single-atom catalysts have advantages such as maximizing atomic utilization,unique electronic structures,and enhanced catalytic activity/selectivity.Especially in the field of biomedicine,metal-based single-atom catalysts have a significant advantage in their high stability in complex physiological environments since they do not produce biological toxicity caused by the aggregation of a large number of metal ions.This review summarized the latest research progress on the types of confinement carriers,performance regulation mechanisms,and applications of single-atom catalysts in the field of biomedicine in recent years.Firstly,the single-atom active sites-loaded carrier is an important component of single-atom catalysts,which has a remarkable influence on the performance of catalysts.In response to the demand for smaller particle size and good biocompatibility of catalyst carriers in the field of biomedicine,this review focused on the research progress of different types of carrier materials such as metal and compound carriers,carbon-based carriers mainly composed of metal organic frameworks,and silica-based carriers for the confined loading of single-atom active sites.Subsequently,based on the relationship between atomic valence states,coordination structures,and performance regulation mechanisms,the biological performance regulation mechanism of bio-applicable single-atom catalysts was discussed in detail.The majority of single-atom active sites are located in the metal single-atom sites of the catalytic center,and the structure of the active center greatly affects its ability to adsorb substrates and intermediate products,as well as the energy required for bonding and cleavage during the catalytic process.Next,we summarized the research progress of single-atom catalysts in different disease models(such as infected wounds,tumors,arthritis diseases,etc.)as well as in fields such as bioimaging and biosensing.Due to their unique atomic-level structure,efficient catalytic properties,and good biosafety,single-atom catalysts provide new possibilities for developing novel and efficient bio-applicable single-atom catalysts with high selectivity and good biocompatibility.Finally,we looked forward to the development and challenges of bio-applicable single-atom catalysts.Currently,there are still some issues such as high preparation costs,further verification of long-term biosafety,mechanisms for enhancing/deactivating catalytic activity in physiological environments,and a certain gap between catalytic activity and natural enzymes.This review aims to deepen people’s understanding of the regulatory mechanisms and biological effects of single-atom catalysts and promote the development of single-atom nanomedicine.